Assessing viability of entering the NSCLC market

  • Analysed clinical and market potential for entry into the NSCLC market

  • Evaluated unmet needs to identify potential entry points

  • Conducted a deep-dive study of key assets and key players


CLIENT CHALLENGES
  • A Japanese pharmaceutical company wanted to assess the viability of entering the NSCLC market
  • Key challenges were :
    • Understanding and assessing the NSCLC market, which has numerous assets
    • Undertaking a competitive assessment of pipeline drugs to identify potential drugs
    • Understanding regulatory approvals, reimbursement and market access in the NSCLC market
    • Evaluating unmet needs, barriers, drivers for charting the wayout
OUR APPROACH
  • Competitive landscape :
    • Understanding the current SoC, and epidemiology of NSCLC
    • Understanding diagnostic tests available and associated treatments available
    • Mapping different assets in the NSCLC pipeline against LOT and target
  • Benchmarking assets :
    • Evaluating the safety and efficacy of approved drugs to understand benchmarking in different patient segments
    • Competitive assessment of pipeline drugs to identify potential drugs
  • Viability assessment :
    • Evaluating unmet needs, barriers, drivers for charting the wayout
    • Understanding the launch timeline, assessment of pricing, reimbursement and CDx considerations
IMPACT DELIVERED
  • Helped the client’s team understand the landscape of the NSCLC market, considering both approved and ongoing trials
  • Advised on viability of entering the NSCLC market using different parameters
Thank you for sharing your details

Your file will start downloading automatically

If it does not download within 1 minute,

Share this on

What we have done

Product launch strategy for European biopharmaceutical company
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Opportunity assessment and market attractiveness for one of the top 10 pharmaceutical major
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Competitor benchmarking and performance gap analysis for a leading European medical device player
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Assessment of GCC pharmaceutical market for a global European pharma major
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Supplier assessment and industry benchmarking for a global top 10 pharmaceutical company
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Research on a multiple sclerosis drug with help from global neurologists
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Procurement in non-Food FMCG Industry
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach